ORIQUMEDIUM SIGNALFINANCIAL10-Q

ORIQU completed its IPO process with full exercise of underwriters' over-allotment option, generating additional proceeds of $9 million while reducing current liabilities by over half.

The full exercise of the over-allotment option indicates strong investor demand for the SPAC offering and provides the company with additional capital for future acquisitions. As a newly public special purpose acquisition company that has not yet commenced operations, ORIQU is now in the phase of seeking suitable merger targets.

Comparing 2025-11-14 vs 2025-08-14View on EDGAR →
FINANCIAL ANALYSIS

The company's balance sheet reflects the completion of its public offering, with current liabilities decreasing meaningfully from $519K to $231K as IPO-related obligations were settled. The additional $9 million raised through the over-allotment option, plus $180,000 from sponsor warrant purchases, strengthens the company's cash position for pursuing acquisition opportunities. The financial profile is consistent with a recently completed SPAC in the pre-acquisition phase.

FINANCIAL STATEMENT CHANGES
Total Liabilities
Balance Sheet
-55.5%
$519K→$231K

Liabilities reduced 55.5% — deleveraging improves balance sheet strength and financial flexibility.

Current Liabilities
Balance Sheet
-55.5%
$519K→$231K

Current liabilities reduced — improved short-term financial position and working capital health.

LANGUAGE CHANGES
NEW — 2025-11-14
PRIOR — 2025-08-14
ADDED
On July 18, 2025, the Underwriters over-allotment option was exercised in full, and the 225,000 ordinary shares were no longer subject to forfeiture.
On July 18, 2025, the Underwriters over-allotment option was exercised in full, and the 225,000 ordinary shares were no longer subject to forfeiture.
On July 18, 2025, the Underwriters over-allotment option was exercised in full, and the 225,000 ordinary shares were no longer subject to forfeiture.
As of September, 30, 2025, the Company had not commenced any operations.
On July 18, 2025, the underwriters fully exercised their over-allotment option to purchase an additional 900,000 units at a purchase price of $ 10.00 per unit, generating additional gross proceeds of $ 9,000,000 .
+7 more — sign up free →
REMOVED
Financial Statements Condensed Balance Sheets as of June 30, 2025 (Unaudited) and December 31, 2024 F-1 Condensed Statements of Operations for the three and six months ended June 30, 2025 (Unaudited) F-2 Condensed Statements of Changes in Shareholders Equity (Deficit) for the three and six months ended June 30, 2025 (Unaudited) F- 3 Condensed Statement of Cash Flows for the six months ended June 30, 2025 (Unaudited) F-4 Notes to condensed financial statements (Unaudited) F- 5 Item 2.
On July 18, 2025, the underwriter s over-allotment option was exercised in full in conjunction with the Initial Public Offering, and the 225,000 ordinary Shares were no longer subject to forfeiture.
F- 1 ORIGIN INVESTMENT CORP I CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED) For the three months ended June 30, 2025 For the six months ended June 30, 2025 EXPENSES General and administrative expenses $ 115,827 $ 120,420 Total expenses 115,827 120,420 NET LOSS ( 115,827 ) ( 120,420 ) WEIGHTED AVERAGE SHARES OUTSTANDING, BASIC AND DILUTED (1) 1,500,000 1,500,000 BASIC AND DILUTED NET LOSS PER SHARE $ ( 0.08 ) $ ( 0.08 ) (1) Excludes up to 225,000 ordinary shares that were subject to forfeiture if the over-allotment option was not exercised in full or in part by the underwriter (see Note 5).
On July 18, 2025, the underwriter s over-allotment option was exercised in full in conjunction with the Initial Public Offering, and the 225,000 ordinary Shares were no longer subject to forfeiture.
On July 18, 2025, the underwriter s over-allotment option was exercised in full in conjunction with the Initial Public Offering, and the 225,000 ordinary Shares were no longer subject to forfeiture.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →